A new trading day began on Monday, with Lineage Cell Therapeutics Inc (AMEX: LCTX) stock price down -0.20% from the previous day of trading, before settling in for the closing price of $0.50. LCTX’s price has ranged from $0.48 to $1.61 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 119.78% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 6.94%. With a float of $218.96 million, this company’s outstanding shares have now reached $220.42 million.
In an organization with 75 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.99%, operating margin of -260.7%, and the pretax margin is -229.91%.
Lineage Cell Therapeutics Inc (LCTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lineage Cell Therapeutics Inc is 0.66%, while institutional ownership is 43.57%. The most recent insider transaction that took place on Nov 26 ’24, was worth 8,850. In this transaction Chief Financial Officer of this company bought 15,000 shares at a rate of $0.59, taking the stock ownership to the 25,500 shares. Before that another transaction happened on Nov 26 ’24, when Company’s General Counsel bought 15,000 for $0.60, making the entire transaction worth $9,000. This insider now owns 22,184 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.94% per share during the next fiscal year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Here are Lineage Cell Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.11 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.76 million. That was better than the volume of 1.09 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 20.53%. Additionally, its Average True Range was 0.05.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 3.07%, which indicates a significant decrease from 10.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.20% in the past 14 days, which was lower than the 90.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7026, while its 200-day Moving Average is $0.9419. However, in the short run, Lineage Cell Therapeutics Inc’s stock first resistance to watch stands at $0.5103. Second resistance stands at $0.5247. The third major resistance level sits at $0.5393. If the price goes on to break the first support level at $0.4813, it is likely to go to the next support level at $0.4667. The third support level lies at $0.4523 if the price breaches the second support level.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
With a market capitalization of 107.60 million, the company has a total of 220,416K Shares Outstanding. Currently, annual sales are 8,950 K while annual income is -21,490 K. The company’s previous quarter sales were 3,780 K while its latest quarter income was -3,030 K.
